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ABSTRACT
Non-infectious diseases, including hypercholesterolemia, are now ranked top 10 in 
Indonesia. Statins are inhibitors of HMG-CoA reductase, an enzyme for biosynthesis of 
cholesterol in the liver. Statins have been proven to reduce the risk of death due to CHD 
and mortality from various reasons. The objective of the study is to know the utilization 
of statins in peripheral area of Indonesia. This retrospective study on utilization of statins 
prescribed for hypercholesterolemia was taken from medical record year of 2014-2015 
of a District Hospital – Dr. Haulussy, Ambon, and Maluku. We collected demographic 
data, pre- and treated concentrations of total cholesterol (TC), low-density lipoprotein 
cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG), 
types and dosages of statins or other lipid-lowering medications given. Student t-test 
using was performed to check statistical differences for all cholesterol and TG differences 
prior to therapy versus during treatment. Eighty three respondents consisted of 26 men 
(31.3%) and 57 women (68.7%) with mean age 60 ± 11 years old. The pre-treatment/
post-treatment values (mg/dL) of TC: 245.22 ± 51.40/224.97 ± 98.79 (p=0.004); 
LDL-C: 166.07 ± 45.36/146.00 ± 41.07; HDL-C: 54.52 ± 37.95/43.00 ± 0.00; and 
TG: 177.36 ± 103.25/121.00 ± 52.87, respectively. Seventy-nine patients (95.2%) 
were treated with statins. The dosage given were 10 mg (n=19, 22.9%), 20 mg (n= 
63, 75.9%), and 40 mg (n=1, 1.2%). Twenty-eight patients (33.7%) had no post-
treatment data of cholesterol, and 31 out of 55 patients (56%) were responders. All 
cholesterol levels were decreased, but responder rate was only 56%. Therefore, dosage 
adjustment and prerequisite cholesterol level during and post-treatment measurement 
should be made regularly.
ABSTRAK
Penyakit non-infeksi, termasuk hiperkolesterolemia, sekarang menduduki peringkat 10 
teratas di Indonesia. Statin adalah inhibitor HMG-CoA reduktase, yaitu enzim untuk 
biosintesis kolesterol di hati. Statin telah terbukti mengurangi risiko kematian akibat 
PJK dan kematian akibat berbagai alasan. Tujuan dari penelitian ini untuk mengetahui 
pemanfaatan statin di daerah periferal Indonesia. Penelitian retrospektif tentang 
pemanfaatan statin yang diresepkan untuk hiperkolesterolemia diambil dari rekam medis 
tahun 2014-2015 dari Rumah Sakit Distrik - Dr. Haulussy, Ambon, dan Maluku. Kami 
mengumpulkan data demografi, konsentrasi pra-perlakuan dan kolesterol Total (TC), 
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kolesterol low-density lipoprotein (LDL-C), kolesterol HDT, dan Trigliserida (TG), jenis 
dan dosis statin atau obat penurun lipid lainnya yang diberikan. Uji t dilakukan untuk 
memeriksa perbedaan statistik untuk semua perbedaan kolesterol dan TG sebelum 
terapi dibandingkan selama pengobatan. Delapan puluh tiga responden terdiri dari 26 
pria (31,3%) dan 57 wanita (68,7%) dengan usia rata-rata 60 ± 11 y.o. Nilai pra-
perawatan/pasca perawatan (mg/dL) dari TC: 245,22 ± 51,40 / 224,97 ± 98,79 (p 
= 0,004); LDL-C: 166.07 ± 45.36/146.00 ± 41.07; HDL-C: 54,52 ± 37,95 / 43,00 
± 0,00; dan TG: 177,36 ± 103,25/121,00 ± 52,87. Tujuh puluh sembilan pasien 
(95,2%) diobati dengan statin. Dosis yang diberikan adalah 10 mg (n = 19, 22,9%), 
20 mg (n = 63; 75,9%), dan 40 mg (n = 1; 1,2%). Dua puluh delapan pasien (33,7%) 
tidak memiliki data pasca perawatan kolesterol, dan 31 dari 55 pasien (56%) adalah 
responden. Semua kadar kolesterol menurun, tetapi tingkat responden hanya 56%. Oleh 
karena itu, penyesuaian dosis dan pengukuran tingkat kolesterol prasyarat selama dan 
pasca perawatan harus dilakukan secara teratur.
Keywords: Statins, drug utilization, hypercholesterolemia, HMG-CoA reductase inhibitor
American Heart Association (ACC/AHA) in 
2013 made another approach which is focused 
not on lowering LDL-C level per se, but make 
statins the linchpin of their recommendation.9 
This notion was made due to lack of clinical 
evidences to support titration of drug therapy 
to specific LDL-C and/or non-HDL-C goals. 
On contrary, the intensity of statin therapy 
did show evidences on reducing the CHD.10 
Evidence suggests that in actual practice it 
is often the goal of decreasing cholesterol 
levels is not achieved especially in developing 
countries. Previous studies showed that there 
is a huge gap on the effectiveness of statin 
used in clinical practice in comparison with 
clinical trials.11-13 
The aim of the study was to investigate 
the utilization of statin in peripheral area of 
Indonesia. The data was gathered from a district 
hospital in Maluku province, Indonesia.
MATERIALS AND MethodS
Subjects
A retrospective study on utilization of 
statins prescribed for hypercholesterolemia 
was conducted by collecting data from medical 
record year of 2014-2015 from District 
INTRODUCTION
Coronary heart disease (CHD) is 
substantially replacing communicable diseases 
in many low- and middle-income countries, 
including Indonesia. And dyslipidemia is one 
of the major risk-factors of CHD. According 
to the latest data metabolic disease is now 
ranked . The first attempt to lower the risk is 
by changing their lifestyles, which include 
reducing the body weight, low animal fat and 
high fibre diet, taking exercise and smoking 
cessation. However, these efforts could only 
reduce the cholesterol level up to 15%.1
Statins are group of lipid-lowering drugs, 
which have been proven by many clinical 
trials not only in lowering the cholesterol 
level but also cardiovascular diseases in 
primary and secondary prevention studies.2-6 
From these short and medium-term clinical 
trial data and long-term clinical studies, the 
National Cholesterol Education Program 
(NCEP) Adult Treatment Panel III (ATP III) 
established targets for LDL-C that depend 
on the individual risk of the patient, with 
the lowest LDL-C targets (<100 mg/dL) 
recommended for patients with CHD or 
other forms of vascular disease.7,8 However, 
recently American College of Cardiology/
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Hospital – Dr. Haulussy, Ambon, Maluku. 
The inclusion criteria were 1) all patients 
diagnosed with primary hypercholesterolemia 
with a value of TC ≥ 240 mg/dL or LDL 
cholesterol: ≥ 160 mg/dL with or without 
other complications (e.g. T2DM); 2) all of the 
above patients who were given statin-lowering 
cholesterol-lowering drugs (HMG-CoA 
reductase inhibitor); 3) statins that are used as 
main drugs or supplemental drugs with other 
cholesterol-lowering. The exclusion criteria 
were 1) all subjects diagnosed not with primary 
hypercholesterolemia; 2) subjects who were 
diagnosed with primary hypercholesterolemia 
but did not receive any statins; 3) subjects 
who have had not measurement of cholesterol 
concentration prior to treatment with statin.
Protocol of study
Patients’ medical records were reviewed 
to select patients who fulfil the inclusion 
and exclusion criteria. The data collection 
form was prepared to collect patients’ 
characteristics (gender and age), diagnosis, 
relevant laboratory value of pre- and during 
treatment i.e. total cholesterol (TC), low-
density lipoprotein cholesterol (LDL-C), high-
density lipoprotein cholesterol (HDL-C), and 
triglyceride (TG), concomitant of diseases 
i.e. T2DM, hypertension, chronic kidney 
diseases), and prescribed medications (types 
of statins or other lipid-lowering medications 
given, and dosages of statins). 
Statistical analysis
Data of cholesterol profile and TG were 
presented as mean ± standard deviation (SD). 
Student t-test was performed using SPSS ver. 
22 to determine statistical differences for all 
cholesterol and TG differences pre treatment 
and at the time the data collected. 
RESULTS
We gathered data from eighty three 
respondents consisted of 26 men (31.3%) and 
57 women (68.7%) with mean of age 60 ± 11 
years old. Seventy nine subjects (95.2%) were 
treated with simvastatin, 3 subjects (3.61%) 
with atorvastatin and 1 patient (1.20%) with 
pravastatin, respectfully. The dosage given 
were 10 mg (n=19, 22.9%), 20 mg (n= 63, 
75.9%), and 40 mg (n=1, 1.2%). Twenty-eight 
subjects (33.7%) had no post-treatment data of 
cholesterol. None of them reached the targeted 
LDL-C concentration of < 100 mg/dL. 
It is clearly shown from TABLE 1 that the 
only parameter for diagnosis and for follow-up 
is total cholesterol and only few were measured 
their non-HDL cholesterol and LDL-C. 
Moreover, very few subjects who were followed-
up to measure the effect of the treatment.









TC 245.22 ± 51.4 (83)
224.97 ± 98.8 
(39) 13.4-64.2 0.004
LDL-C 166.07 ± 45.4 (27)
146.00 ± 41.1 
(3) -111.4-174 0.445
HDL-C 54.52 ± 37.95 (25)
43.00 ± 0.00 
(2) -97.35 – 131 0.310
TG 177.36 ± 103.2 (28)
121.00 ± 52.87 
(5) -97.37 – 137 0.661
J Med Sci, Volume 50, No. 2, 2018 April: 209-215
212
TABLE 2 shows that only 14.45% of 
subjects are diagnosed with dyslipidaemia 
and the rest of them having comorbidities 
such as hypertension, type 2 diabetes mellitus 
(T2DM), and chronic kidney diseases (CKD).







Dyslipidaemia + hypertension 38 45.78
Dyslipidaemia + T2DM 17 20.48
Dyslipidaemia + hypertension + T2DM 15 18.07
Dyslipidaemia + CKD 1 1.20
Total 83 99.98
Legend: T2DM=type 2-Diabetes Mellitus, CKD=chronic kidney disease
 
TABLE 3. Cases of dyslipidaemia subjects who have had comorbid and treated with simvastatin
Medical 
record No. Sex Age Comorbid
Type & dosage of statin – Intensity 
therapy 
027810 F 50 T2DM, Hypertension Simvastatin, 20 mg, MI
000166 F 51 T2DM, Hypertension Simvastatin, 20 mg, MI
181971 F 52 T2DM, Hypertension Simvastatin, 20 mg, MI
138527 M 51 T2DM Simvastatin, 20 mg, MI
029457 F 53 T2DM Simvastatin, dose n/a
006518 F 67 Hypertension Simvastatin, dose n/a
Legend: T2DM=Type2-Diabetes Mellitus, MI = moderate-intensity statin therapy
TABLE 3 shows cases of dyslipidaemia 
subjects who have had comorbid and treated 
with simvastatin. 
TABLE 4 shows the percentage reduction 
of number of subjects who did not take routine 
check-up for their cholesterol level. It appears 
that measurements of total cholesterol, LDL, 
HDL and TG levels were not consistent.
 TABLE 4. Percentage reduction in the number of subjects who re-examined cholesterol levels
Cholesterol
Number of subjects % of decrease of subjects who 
did follows-upPre-treatment At the time of observation
TC 83 39 53
LDL-C 27 3 89
HDL-C 25 2 92
TG 28 5 82
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DISCUSSION
Total Cholesterol, LDL-C, and TG levels 
were decreased, but only TC was significantly 
decreased. However, none of these results 
reached the target level, and responder rate was 
only 56%. This inefficacy most likely caused 
by inappropriate of dosing, incompliant, and 
lack of laboratory monitoring. This was also 
in accordance to other studies conducted 
in three hospitals in Jakarta, Indonesia.13 
However, other statins, such as atorvastatin, 
rosuvastatin, pravastatin and lovastatin were 
used in those three hospitals, and it was shown 
also that atorvastatin was more effective 
compared to other statins. 
TABLE 2 shows that more than 85% 
subjects were diagnosed not only dyslipidaemia 
but also with other comorbid. The most 
comorbid observed were subjects with 
hypertension (38 subjects, 45.78%), T2DM (17 
subjects, 20.48%), hypertension and T2DM (15 
subjects, 18.07%), and CKD (1 patient, 1.20%), 
respectively. However, if we observed the 
dosage of the simvastatin, it was shown that all 
subjects received the same dosage, regardless 
of the cholesterol concentration they had and 
their comorbidities (TABLE 3). Adjustment of 
statin dose should be done regularly according 
to the cholesterol levels as well as existing 
comorbidities and in accordance to the newest 
guidelines.7,14,15 With regards to the issues on 
the relationship between statins and T2DM, 
we do not know whether there are new-onset 
of T2DM emerged among the subjects in our 
study. Some studies reported that all statins 
have the potency to increase the incident, but 
other studies mentioned that the evidence is 
not firm yet.16 Although, in JUPITER study, 
rosuvastatin 20 mg versus placebo, has high 
hazard ratio (HR: 1.25, 95% CI, 1.05-1.49) and 
in CORONA study (rosuvastatin 10 mg versus 
placebo) with RR 1.13 (95% CI, 0.86-1.50). 
Whereas, simvastatin, as it is most prescribed 
statin in this hospital, has lower RR.17 Other 
aspect that should be considered, what is 
the impact of statins on glycaemic control 
in subjects with DM? Due to insufficient 
methodological approaches and data, experts 
could not draw a firm conclusion on that issue. 
The available data suggest that, statin impacts 
on glycaemia control is very small (mean 
increase of ≈ 0.3% or less). 
The use of statins in peripheral areas 
often could not follow the guidelines. Various 
factors underlie this issue. As it is shown in 
TABLE 3, most of the subjects did not take 
regular check-up for monitoring their therapy. 
Findings from previous research indicate 
that lack of medication adherence, follow-up 
examination of treatment outcomes by doctors, 
routine cholesterol checks and other clinical 
examinations are commonplace in health care 
facilities in developing countries. 
Nevertheless, since 4 years, Indonesia has 
been running a system of national health services 
named Jaringan Kesehatan Nasional-Badan 
Penyelenggara Jaminan Sosial (National 
Health Network – Social Security Assurance 
Agency) that applies to the whole community. 
Prior to this program, the people should pay 
from their own pocket for any health services 
they received. This could be the reason why 
most of the subjects did not comply with the 
guidelines. Through this program, it is hoped 
that the above problems will no longer occur. 
Initial examination and follow-up examination 
can be performed regularly, so monitoring 
the success of therapy can be guaranteed. 
Therefore, a further study to compare of health 
service in pre- and JKN-BPJS era, with regards 
to metabolic diseases should be considered.
CONCLUSION
Utilization of statins in Ambon District 
Hospital, Maluku can decrease all cholesterol 
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levels were decreased. However, the responder 
rate is only 56%. Therefore, dosage adjustment 
and prerequisite cholesterol level during and 
post-treatment measurement should be made 
regularly.
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